Use of administrative claims data in observational studies of antirheumatic medication effects on pregnancy outcomes: a scoping review protocol.

Autor:	Tharmarajah S; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada., Guilcher S; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.; Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada., Santhireswaran A; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada., McCarthy L; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.; Institute for Better Health, Trillium Health Partners, Mississauga, ON, Canada.; Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada., Mahendira D; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada., Berger H; Department of Obstetrics and Gynecology, St. Michael's Hospital, Toronto, ON, Canada., Tadrous M; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.; Women's College Research Institute, Women's College Hospital, Toronto, ON, Canada.
Jazyk:	angličtina
Zdroj:	JBI evidence synthesis [JBI Evid Synth] 2024 Jan 01; Vol. 22 (1), pp. 106-115. Date of Electronic Publication: 2024 Jan 01.
DOI:	10.11124/JBIES-23-00039
Abstrakt:	Objective: The primary objective of this review is to examine which disease-modifying antirheumatic drugs (DMARDs) and biologics used to treat pregnant individuals with rheumatic conditions have been reported in observational studies using population-based health administrative data. The secondary objective is to describe which adverse pregnancy outcomes (both maternal and neonatal) have been reported, their definitions, and corresponding diagnostic and/or procedural codes. Introduction: Pregnant individuals are typically excluded from drug trials due to unknown potential risks to both the pregnant person and fetus, leaving most antirheumatic drugs understudied for use in pregnancy. Despite these substantial knowledge gaps, most pregnant individuals continue to be maintained on antirheumatic medications due to the benefits generally outweighing the risks. In contrast to previous systematic reviews of findings from randomized trials, our scoping review aims to leverage this real-world data to generate real-world evidence of antirheumatic drug safety during pregnancy. Inclusion Criteria: Articles must report on observational studies using population-based health administrative data from pregnant individuals with rheumatic conditions (rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, and psoriatic arthritis) receiving antirheumatic drug therapy (DMARDs and biologics). Randomized trials, reviews, case studies, opinion pieces, and abstracts will be excluded. Methods: Electronic databases (MEDLINE [Ovid], Embase [Ovid], CINAHL [EBSCOhost]) and gray literature (OpenGrey, Health Services Research Projects in Progress, World Health Organization Library, and Google Scholar) will be searched for relevant evidence. Search terms will combine 4 concepts: rheumatic diseases, drug therapy, pregnancy, and health care administrative data. Identified articles will be independently screened, selected, and extracted by 2 researchers. Data will be analyzed descriptively and presented in tables. Review Registration: Open Science Framework https://osf.io/5e6tp. Competing Interests: The authors declare no conflict of interest in this project. (Copyright © 2023 JBI.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu